超级效应还是方法学缺陷：质疑胰高血糖素样肽-1受体激动剂与癌症的关系 - Suppr

Super effect or methodological flaw: questioning the glucagon-like peptide-1 receptor agonist cancer narrative.

作者信息

Maier Gregor A, Rathmann Wolfgang, Kuß Oliver

机构信息

Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.

German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany.

出版信息

Diabetologia. 2025 Sep 8. doi: 10.1007/s00125-025-06538-9.

DOI:10.1007/s00125-025-06538-9

PMID:40924113

Abstract

摘要

相似文献

Super effect or methodological flaw: questioning the glucagon-like peptide-1 receptor agonist cancer narrative.超级效应还是方法学缺陷：质疑胰高血糖素样肽-1受体激动剂与癌症的关系

Diabetologia. 2025 Sep 8. doi: 10.1007/s00125-025-06538-9.

Super effect or methodological flaw: questioning the glucagon-like peptide-1 receptor agonist cancer narrative. Reply to Maier GA, Rathmann W, Kuß O [letter].超级效应还是方法学缺陷：质疑胰高血糖素样肽-1受体激动剂与癌症的关系。对迈尔·G·A、拉特曼·W、库斯·O [信件]的回复

Diabetologia. 2025 Sep 4. doi: 10.1007/s00125-025-06526-z.

Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes.孕前使用胰高血糖素样肽-1受体激动剂与不良产科结局风险降低相关。

Am J Obstet Gynecol. 2025 Jan 21. doi: 10.1016/j.ajog.2025.01.019.

A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer.一项观察性研究的系统评价和荟萃分析，评估肠促胰岛素治疗与胰腺癌风险之间的关系。

Pharmacoepidemiol Drug Saf. 2023 Feb;32(2):107-125. doi: 10.1002/pds.5550. Epub 2022 Dec 11.

Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.胰岛素-胰高血糖素样肽-1 受体激动剂接力和胰高血糖素样肽-1 受体激动剂一线治疗方案在 2 型糖尿病患者中的随机、开放标签试验研究。

J Diabetes Investig. 2022 Jun;13(6):965-974. doi: 10.1111/jdi.13749. Epub 2022 Feb 8.

Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1（GLP-1）受体激动剂。

Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.

Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials.胰高血糖素样肽1（GLP-1）受体激动剂在孕期的使用：来自监管临床试验的安全性数据。

Diabetes Obes Metab. 2025 May 6. doi: 10.1111/dom.16437.

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db mice.替尔泊肽，一种双重葡萄糖依赖性胰岛素促分泌多肽/胰高血糖素样肽 1 受体激动剂，在肥胖 2 型糖尿病 db/db 小鼠中对胰岛β细胞和肝脂肪变性具有有利影响。

Diabetes Obes Metab. 2024 Dec;26(12):5982-5994. doi: 10.1111/dom.15972. Epub 2024 Sep 30.

Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.胰高血糖素样肽-1受体激动剂与基础胰岛素的固定比例组合：一项系统评价和荟萃分析。

Endocrine. 2017 Jun;56(3):485-494. doi: 10.1007/s12020-017-1293-6. Epub 2017 Apr 12.

A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.多囊卵巢综合征患者 GLP-1 对人体测量学、代谢和内分泌参数影响的系统评价

Womens Health (Lond). 2024 Jan-Dec;20:17455057241234530. doi: 10.1177/17455057241234530.

本文引用的文献

Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes.胰高血糖素样肽-1受体激动剂与2型糖尿病患者的胃肠道癌症风险

Diabetologia. 2025 Jun 5. doi: 10.1007/s00125-025-06453-z.

Too good to be true: Are GLP-1 receptor agonists the new metformin?好得难以置信：GLP-1 受体激动剂是新型二甲双胍？

J Diabetes Complications. 2024 Oct;38(10):108851. doi: 10.1016/j.jdiacomp.2024.108851. Epub 2024 Aug 30.

Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.胰高血糖素样肽 1 受体激动剂与 2 型糖尿病患者的 13 种肥胖相关癌症。

JAMA Netw Open. 2024 Jul 1;7(7):e2421305. doi: 10.1001/jamanetworkopen.2024.21305.

Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators.药物流行病学的核心概念：指示性混杂和活性对照物的作用。

Pharmacoepidemiol Drug Saf. 2022 Mar;31(3):261-269. doi: 10.1002/pds.5407. Epub 2022 Jan 27.

Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations.降糖药物与心血管结局关联的观察性研究：应对方法学局限性

Diabetologia. 2014 Nov;57(11):2237-50. doi: 10.1007/s00125-014-3364-z. Epub 2014 Sep 12.

Metformin and the risk of cancer: time-related biases in observational studies.二甲双胍与癌症风险：观察性研究中的时间相关性偏倚。

Diabetes Care. 2012 Dec;35(12):2665-73. doi: 10.2337/dc12-0788.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Super effect or methodological flaw: questioning the glucagon-like peptide-1 receptor agonist cancer narrative.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献